Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifibrinolytic Agents | 2 | 2025 | 64 | 1.030 |
Why?
|
| Tranexamic Acid | 2 | 2025 | 59 | 1.020 |
Why?
|
| Hemorrhage | 3 | 2025 | 822 | 0.890 |
Why?
|
| Wounds and Injuries | 2 | 2025 | 961 | 0.590 |
Why?
|
| Cohort Studies | 7 | 2025 | 6013 | 0.560 |
Why?
|
| Outpatients | 4 | 2025 | 447 | 0.490 |
Why?
|
| South Africa | 4 | 2025 | 266 | 0.360 |
Why?
|
| Birth Weight | 1 | 2014 | 514 | 0.340 |
Why?
|
| Gestational Age | 1 | 2014 | 987 | 0.330 |
Why?
|
| Anemia, Sickle Cell | 3 | 2021 | 318 | 0.320 |
Why?
|
| Antibodies, Neutralizing | 4 | 2025 | 340 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 443 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 5 | 2025 | 1505 | 0.250 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 910 | 0.240 |
Why?
|
| Crush Injuries | 1 | 2025 | 14 | 0.230 |
Why?
|
| Risk Assessment | 1 | 2014 | 3747 | 0.220 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 133 | 0.210 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2024 | 15 | 0.200 |
Why?
|
| Freeze Drying | 1 | 2024 | 81 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 412 | 0.190 |
Why?
|
| Clinical Decision-Making | 1 | 2026 | 363 | 0.190 |
Why?
|
| Violence | 1 | 2025 | 279 | 0.180 |
Why?
|
| Plasma | 1 | 2024 | 223 | 0.180 |
Why?
|
| Probability | 1 | 2023 | 307 | 0.180 |
Why?
|
| Trauma Centers | 1 | 2025 | 466 | 0.180 |
Why?
|
| Blood Coagulation | 2 | 2021 | 274 | 0.170 |
Why?
|
| Adult | 13 | 2026 | 40777 | 0.170 |
Why?
|
| Atherosclerosis | 1 | 2024 | 409 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2023 | 1374 | 0.150 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2025 | 453 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1327 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2025 | 8057 | 0.150 |
Why?
|
| Renal Circulation | 1 | 2019 | 75 | 0.150 |
Why?
|
| Factor Xa Inhibitors | 1 | 2021 | 194 | 0.140 |
Why?
|
| Rivaroxaban | 1 | 2021 | 271 | 0.140 |
Why?
|
| Albuminuria | 1 | 2019 | 189 | 0.140 |
Why?
|
| Computer Simulation | 1 | 2023 | 1003 | 0.140 |
Why?
|
| Anxiety | 1 | 2025 | 1118 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 875 | 0.130 |
Why?
|
| Peripheral Arterial Disease | 1 | 2024 | 507 | 0.130 |
Why?
|
| Protein S Deficiency | 1 | 2016 | 8 | 0.120 |
Why?
|
| Humans | 19 | 2026 | 145474 | 0.120 |
Why?
|
| Phosphatidylserines | 1 | 2016 | 62 | 0.120 |
Why?
|
| Middle Aged | 9 | 2025 | 36215 | 0.120 |
Why?
|
| Male | 12 | 2026 | 72842 | 0.120 |
Why?
|
| Hospitalization | 4 | 2022 | 2460 | 0.110 |
Why?
|
| Thrombin | 1 | 2016 | 172 | 0.110 |
Why?
|
| District of Columbia | 1 | 2014 | 38 | 0.110 |
Why?
|
| Virginia | 1 | 2014 | 57 | 0.110 |
Why?
|
| Maryland | 1 | 2014 | 67 | 0.110 |
Why?
|
| Female | 12 | 2026 | 78844 | 0.110 |
Why?
|
| Maternal Age | 1 | 2014 | 128 | 0.110 |
Why?
|
| Risk Factors | 5 | 2025 | 10885 | 0.100 |
Why?
|
| Neutropenia | 1 | 2014 | 154 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 956 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2015 | 310 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 668 | 0.090 |
Why?
|
| Educational Status | 1 | 2014 | 466 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2016 | 3623 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2016 | 748 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 485 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 881 | 0.070 |
Why?
|
| Mothers | 1 | 2014 | 765 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2013 | 1038 | 0.070 |
Why?
|
| beta-Thalassemia | 2 | 2019 | 40 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2021 | 608 | 0.070 |
Why?
|
| Smoking | 1 | 2014 | 1472 | 0.070 |
Why?
|
| Aged | 7 | 2025 | 26153 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1581 | 0.060 |
Why?
|
| Length of Stay | 1 | 2013 | 1349 | 0.060 |
Why?
|
| Mass Screening | 1 | 2015 | 1360 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 1419 | 0.060 |
Why?
|
| Likelihood Functions | 1 | 2026 | 138 | 0.060 |
Why?
|
| Palliative Care | 1 | 2014 | 1020 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2021 | 2062 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 1891 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2025 | 11772 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2026 | 241 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2024 | 102 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2014 | 6447 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 2382 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 2214 | 0.050 |
Why?
|
| Urban Population | 1 | 2025 | 493 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2022 | 360 | 0.040 |
Why?
|
| Resuscitation | 1 | 2024 | 310 | 0.040 |
Why?
|
| Infant | 1 | 2014 | 10077 | 0.040 |
Why?
|
| Sickle Cell Trait | 1 | 2019 | 15 | 0.040 |
Why?
|
| Hydroxyurea | 1 | 2019 | 34 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 5904 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 229 | 0.030 |
Why?
|
| Neoplasms | 1 | 2013 | 2906 | 0.030 |
Why?
|
| Protein S | 1 | 2016 | 10 | 0.030 |
Why?
|
| Prothrombin | 1 | 2016 | 25 | 0.030 |
Why?
|
| Antithrombin III | 1 | 2016 | 18 | 0.030 |
Why?
|
| Thrombomodulin | 1 | 2016 | 15 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 992 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2016 | 92 | 0.030 |
Why?
|
| Thrombophilia | 1 | 2016 | 89 | 0.030 |
Why?
|
| Vaccination | 1 | 2024 | 1426 | 0.030 |
Why?
|
| Culture | 1 | 2015 | 124 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2014 | 2 | 0.030 |
Why?
|
| Mammography | 1 | 2015 | 166 | 0.030 |
Why?
|
| Depression | 1 | 2024 | 1546 | 0.030 |
Why?
|
| Health Surveys | 1 | 2015 | 518 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2016 | 379 | 0.020 |
Why?
|
| Heart Failure | 1 | 2026 | 2326 | 0.020 |
Why?
|
| Perception | 1 | 2015 | 378 | 0.020 |
Why?
|
| Thrombosis | 1 | 2016 | 400 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 6066 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17291 | 0.020 |
Why?
|
| United States | 3 | 2015 | 16098 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2014 | 536 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 1323 | 0.020 |
Why?
|
| Rural Population | 1 | 2015 | 659 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 3116 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 2406 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 8333 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 14218 | 0.010 |
Why?
|